IL-17A-induced NETs are profibrogenic in mice with metabolic dysfunction-associated steatotic liver disease (MASLD)
The Journal of Immunology · 2026
DOI: 10.1093/jimmun/vkaf332 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, 2026. Verfasst von Mohamed N Abdelnabi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Centre de Recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC H2X 0A9, Canada. Hauptthemen laut MEDLINE: Interleukin-17, Neutrophils, Extracellular Traps, Liver Cirrhosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Canadian Institutes of Health Research (CIHR).
Abstract (Originalsprache)
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing epidemic with limited therapeutic options. Interleukin (IL)-17A, a proinflammatory cytokine produced by both innate and adaptive immune cells, has been implicated in MASLD-related inflammation and fibrosis. Although many studies have focused on IL-17A-producing lymphocytes, the role of innate immune cells like neutrophils recruited in response to and capable of producing IL-17A, is less well-characterized. Additionally, neutrophil extracellular traps (NETs), are observed in different chronic liver diseases and correlate with disease severity. Here, we sought to determine the kinetics of IL-17A-producing neutrophils during MASLD-related fibrosis and examine the effect of IL-17 on NET formation, contributing as such to liver fibrosis. Using a mouse model of MASLD induced by high-fat diet (HFD) feeding for 15 or 30 weeks (WK) and in vitro studies, we observed a significant increase in intrahepatic IL-17A-producing neutrophils and NET formation in mice fed the HFD for 30 WK as compared to mice on HFD for 15 WK or controls. NET formation was strongly associated with liver injury and advanced fibrosis. Importantly, treatment with IL-17A induced NET formation in isolated neutrophils. IL-17A-induced NETs activated hepatic stellate cells (HSCs), induced expression of fibrogenic genes, and enhanced their migration in a wound-healing assay. All these are critical processes in fibrosis development. In conclusion, our results suggest that IL-17A-producing neutrophils, via the triggering of NET formation, play a key profibrogenic role in MASLD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre de Recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC H2X 0A9, Canada.
- Département de microbiologie, infectiologie et immunologie, Faculté de médecine, Université de Montréal, Montréal, QC H3C 3J7, Canada.
- Département de pathologie et biologie cellulaire, Faculté de médecine, Université de Montréal, Montréal, QC H3C 3J7, Canada.
- Département de médecine, Faculté de médecine, Université de Montréal, Montréal, QC H3C 3J7, Canada.
ORCID-Profile: Naglaa H Shoukry
Förderung
- Canadian Institutes of Health Research (CIHR)
Zitieren
APA
Abdelnabi, M. N., Maali, Y., Dabbaghizadeh, A., Mokariasl, N., Dion, J., Yamak, R., Soucy, G., Hassan, G. S., & Shoukry, N. H. (2026). IL-17A-induced NETs are profibrogenic in mice with metabolic dysfunction-associated steatotic liver disease (MASLD). The Journal of Immunology. https://doi.org/10.1093/jimmun/vkaf332
Vancouver
Abdelnabi MN, Maali Y, Dabbaghizadeh A, Mokariasl N, Dion J, Yamak R, et al. IL-17A-induced NETs are profibrogenic in mice with metabolic dysfunction-associated steatotic liver disease (MASLD). The Journal of Immunology. 2026. doi:10.1093/jimmun/vkaf332
BibTeX
@article{Abdelnabi2026,
author = {Abdelnabi, Mohamed N and Maali, Yousef and Dabbaghizadeh, Afrooz and Mokariasl, Niloufar and Dion, Jessica and Yamak, Raya and Soucy, Geneviève and Hassan, Ghada S and Shoukry, Naglaa H},
title = {IL-17A-induced NETs are profibrogenic in mice with metabolic dysfunction-associated steatotic liver disease (MASLD)},
journal = {The Journal of Immunology},
year = {2026},
doi = {10.1093/jimmun/vkaf332}
}
EUVIMED